title: Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator: an overview.
abstract: The antitumor and metastasis-inhibitory activities, mode of action, and clinical application of lentinan, a strictly purified beta-1,6:beta-1,3-glucan, are reviewed. Lentinan exerts a prominent antitumor effect and prevents chemical and viral oncogenesis. The antitumor action of lentinan is host-mediated. Compared to other well-known immunostimulants, such as bacille Calmette Guérin (BCG), Corynebacterium parvum, and lipopolysaccharide (LPS), lentinan appears to represent a unique class of immunopotentiator, a T cell-oriented adjuvant. Lentinan triggers the increased production of various kinds of bioactive serum factors associated with immunity and inflammation, such as IL-1, CSF, IL-3, vascular dilation inducer, and acute-phase protein inducer, by the direct impact of macrophages or indirectly via lentinan-stimulated T cells, which results in the induction of many immunobiological changes in the host. Augmented IL-1 production amplifies the maturation of immature effector cells to mature cells capable of responding to lymphokines such as IL-2 and T cell-replacing factors. Because of this mode of action, intact T cell compartments for antitumor activity of lentinan are required. Lentinan has little toxic side effects. Excellent results were obtained in a 4 year follow-up of the randomized control study of lentinan in phase III on patients with advanced and recurrent stomach and colorectal cancer.
authors.affiliation: National Cancer Center Research Institute, Tokyo, Japan.
authors.forename: G
authors.initials: G
authors.lastname: Chihara
authors.forename: J
authors.initials: J
authors.lastname: Hamuro
authors.forename: Y Y
authors.initials: YY
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Shiio
authors.forename: T
authors.initials: T
authors.lastname: Suga
authors.forename: N
authors.initials: N
authors.lastname: Takasuka
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000970:Antineoplastic Agents; D007167:Immunotherapy; D007912:Lentinan / Q000627:therapeutic use*; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009374:Neoplasms, Experimental / Q000473:pathology / Q000628:therapy*; D011134:Polysaccharides / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D011134:Polysaccharides; D007912:Lentinan